Table 2 Effect estimates from multivariable-adjusted Cox regression models for the effect of cytogenetic high-risk abnormalities on overall survival in the entire cohort and patient subgroups

From: Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma

Parameter

Reference

HR (95% CI)

P-value

Effect of multiple HRA in the entire cohort (using ISS, n=1181)

 1 HRA

0 HRA

1.65 (1.32–2.05)

<0.001

 2 HRA

0 HRA

3.15 (2.00–4.96)

<0.001

Effect of multiple HRA in the entire cohort (using R-ISS, n=1087)

 1 HRA

0 HRA

1.47 (1.16–1.86)

0.001

 2 HRA

0 HRA

2.69 (1.69–4.30)

<0.001

Effect of specific HRA in the entire cohort (using ISS, n=1181)

 del(17p)

Absence of del(17p)

1.64 (1.29–2.08)

<0.001

 HRT

Absence of HRT

1.78 (1.39–2.30)

<0.001

Effect of specific HRA in the entire cohort (using R-ISS, n=1087)

 del(17p)

Absence of del(17p)

1.49 (1.16–1.91)

0.002

 HRT

Absence of HRT

1.62 (1.24–2.11)

<0.001

Effect of specific additional HRA (using ISS, n=164 and n=154)

 del(17p)+HRT

Isolated del(17p)

2.08 (1.19–3.63)

0.010

 del(17p)+HRT

Isolated HRT

1.86 (1.07–3.22)

0.027

  1. Abbreviations: CI, confidence interval; HR, hazard ratio; HRA, cytogenetic high-risk abnormality. HRT: High-risk translocation.
  2. All models were adjusted for age, sex, International Staging System (ISS) or revised ISS (R-ISS) stage, and first-line therapy (immunomodulator, proteasome inhibitor, upfront autologous hematopoietic stem cell transplantation).
Back to article page